Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial

Zhu, Feng‐Cai; Chen, Wen; Hu, Yue‐Mei; Hong, Ying; Li, Juan; Zhang, Xun; Zhang, Yi‐Ju; Pan, Qin‐Jing; Zhao, Fang‐Hui; Yu, Jia‐Xi; Zhang, Yan‐Shu; Yang, Xiaoping; Zhang, Cheng‐Fu; Tang, Haiwen; Zhang, Helen; Lebacq, Marie; David, Marie‐Pierre; K Datta, Sanjoy; Struyf, Frank; Bi, Dan; Descamps, Dominique; the HPV‐039 study group, for

doi:10.1002/ijc.28897

Public

Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial

Shared by NobleBlocks on May 20, 2014 • 12:00 AM UTC

Authors:

Feng‐Cai Zhu

Wen Chen

Yue‐Mei Hu

Abstract

This phase II/III, double‐blind, randomized trial assessed the efficacy, immunogenicity and safety of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in young Chinese women ( ClinicalTrials.gov registration NCT00779766). Women aged 18–25 years from Jiangsu province were randomized (1:1)...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!